The Orla Board has a track record of success in scientific innovation, commercial biotechnology, product launch and early stage investment. The Scientific Team in Orla led by Dr Deepan Shah has many years’ experience in molecular biology and protein design and manufacture.
Dr Dale Athey, Chief Executive Officer
Dr Athey leads and manages the business overall. He is a co-founder of Orla with Jeremy Lakey, Orla’s Scientific Director. Dale has over 20 years’ experience in clinical diagnostics, including extensive commercial experience in customer-facing roles with global companies such as Bayer and Chiron Diagnostics.
Prof Jeremy Lakey, Scientific Director
Prof Lakey leads Orla’s scientific strategy, focusing on R&D that develops Orla’s overall business strategy. Professor of Structural Biochemistry, University of Newcastle upon Tyne, UK and a former BBSRC Research Development Fellow, Jeremy is a world-renowned expert on proteins, which emphasises the credibility of Orla’s technology and provides the company with continued technology streams.
Dr Frank Roberts, Non-Executive Chairman
Dr Roberts has over 20 years of management and leadership experience in the bioprocess and bioscience industries. Frank established and managed the biotechnology company Bioprocessing Limited growing it from start-up, pre-revenue stage through to profitability and ultimate sale to Millipore for $20M in 1999
Dr Roger Duggan, Non-Executive Director and Investor
Dr Duggan has over 30 years of technical and commercial experience in the In Vitro Diagnostic (IVD) industry. Roger previously held posts as Scientific Director, Managing Director and latterly Chief Executive Officer at specialist immunoassay company Immunodiagnostic Systems (IDS) plc growing Group revenues from £4.4M at flotation to £37M in 2010.
Rajen Shah, Non-Executive Director and Investor
Mr Shah is an accomplished technology architect with an exceptional record of achievement in enhancing the value of small businesses. Prior roles include senior product management at Microsoft, CTO at Spryance and senior technical design at high growth CRM companies Scopus (sold to Siebel) and Octane (sold to Epiphany). Rajen was most recently CTO and investor at Avadhi Finance & Technology.